Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation

v3.23.1
Stock-Based Compensation
9 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

Note 7. Stock-Based Compensation

 

In June 2020, the Board of Directors adopted the 2020 Stock Incentive Plan, which provided for the grant of qualified incentive stock options and nonqualified stock options or other awards to the Company’s employees, officers, directors, advisors, and outside consultants for the purchase of up to 1,650,000 shares of the Company’s common stock. On October 22, 2021, the Company’s stockholders approved an increase of the total authorized shares to 3,650,000 shares. Other awards include restricted stock, restricted stock units, stock appreciation rights and other stock-based awards. Other stock-based awards are awards valued in whole or in part by reference to, or are otherwise based on, shares of common stock. Stock options generally vest over a four-year period, at achievement of a performance requirement, or upon change of control (as defined in the applicable plan). The awards expire in five to ten years from the date of grant. In September 2020, the Company awarded 982,500 shares of restricted common stock to its former Chief Executive Officer. As of March 31, 2023, the Company had 594,187 shares available for future issuance under the 2020 Stock Incentive Plan.

 

The Company estimates the fair value of stock-based compensation utilizing the Black-Scholes option pricing model, which is dependent upon several variables, such as assumptions the Company makes for the volatility of its common stock, the expected term of the stock options, the risk-free interest rate for a period that approximates the expected term, and expected dividend yield. Each of these inputs is subjective and generally requires significant judgement to determine. Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period of the respective award.

 

The following table summarizes the range of key assumptions used to determine the fair value of stock options granted during the three and nine months ended March 31, 2023 and 2022.

 

   

Three Months Ended

March 31,

   

Nine Months Ended

March 31,

 
    2023     2022     2023     2022  
Risk-free interest rate     %     1.29% – 2.14 %     2.87% – 4.32 %     0.79% – 2.14 %
Expected term (in years)           4.5       4.56.25       3.04.5  
Expected volatility     %     50.0 %     50.060.0 %     50 %
Expected dividend yield                        

 

The following table summarizes stock option activity for the nine months ended March 31, 2023:

 

   

Number

of

Shares

   

Weighted

Average Exercise

Price

   

Weighted

Average

Remaining

Contractual

Term

(Years)

   

Aggregate

Intrinsic

Value

 
                         
Outstanding at June 30, 2022     1,911,459     $ 4.63       4.4       -  
Granted     172,654     $ 3.31                  
Exercised     (24,000 )   $ 2.18                  
Forfeited     (10,800 )   $ 6.00                  
Outstanding at March 31, 2023     2,049,313     $ 4.54       4.0     $ 415,956  
Options exercisable at March 31, 2023     661,867     $ 4.33       3.4       250,815  

 

The grant date fair value of options awarded during the nine months ended March 31, 2023 was approximately ($1.86) per share. As of March 31, 2023, unrecognized stock-based compensation expense related to unvested stock options totaled approximately $2.7 million which is expected to be recognized over a weighted average period of 2.9 years.

 

The Company recorded stock-based compensation expenses for the following periods:

 

                         
    Three Months Ended     Nine Months Ended  
    March 31,     March 31,  
    2023     2022     2023     2022  
Research and development   $ -     $ 245     $ -     $ 12,233  
General and administrative     223,637       125,009       661,158       241,476  
Total stock-based compensation expense   $ 223,637     $ 125,254     $ 661,158     $ 253,709